Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb 17:10:124.
doi: 10.12688/f1000research.51094.1. eCollection 2021.

Case Report: Ziprasidone induced neuroleptic malignant syndrome

Yub Raj Sedhai  1 , Alok Atreya  2 , Prabin Phuyal  3 , Soney Basnyat  4 , Sagar Pokhrel  5
Affiliations
Case Reports

Case Report: Ziprasidone induced neuroleptic malignant syndrome

Yub Raj Sedhai et al. F1000Res. .

Abstract

Neuroleptic malignant syndrome (NMS) is a well-recognized neurologic emergency. It presents with classic features including hyperthermia, autonomic instability, muscle hypertonia, and mental status changes. The syndrome is potentially fatal and is associated with significant morbidity due to complications such as rhabdomyolysis, acute kidney injury, and ventricular arrhythmias due to the trans-cellular electrolyte shift. NMS is conventionally associated with the first-generation antipsychotic agents, however, has been described with the use of atypical and novel antipsychotics including Ziprasidone. A case of NMS with Ziprasidone use at the therapeutic dose is reported here.

Keywords: Neuroleptic Malignant Syndrome (NMS); Neurologic emergency; Parkinson’s disease; Ziprasidone.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. ECG showing symmetrical T-wave inversions in leads V1 through V6 and QTc of 458 milliseconds.
See this image and copyright information in PMC

References

    1. Strawn JR, Keck PE, Jr, Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870–6. 10.1176/ajp.2007.164.6.870 - DOI - PubMed
    1. Caroff SN, Mann SC: Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185–202. 10.1016/s0025-7125(16)30278-4 - DOI - PubMed
    1. Kogoj A, Velikonja I: Olanzapine induced neuroleptic malignant syndrome--a case review. Hum Psychopharmacol. 2003;18(4):301–9. 10.1002/hup.483 - DOI - PubMed
    1. Murri MB, Guaglianone A, Bugliani M, et al. : Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis. Drugs R D. 2015;15(1):45–62. 10.1007/s40268-014-0078-0 - DOI - PMC - PubMed
    1. Berardi D, Amore M, Keck PE, Jr, et al. : Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: A case-control study. Biol Psychiatry. 1998;44(8):748–54. 10.1016/s0006-3223(97)00530-1 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources